The effects of sacubitril/valsartan compared to valsartan on left ventricular remodelling in patients with asymptomatic left ventricular systolic dysfunction after myocardial infarction: A randomized, double blinded active-comparator cardiac-MR based trial
Heart attacks can cause permanent damage to the heart muscle. If severe, over time the heart will be weakened and unable to efficiently pump blood around the body. This is called heart failure, which is debilitating and has poor life expectancy. In this clinical trial, Professor John Murray and colleagues will compare how well different treatments preserve heart muscle function in 100 people who have evidence of muscle damage after heart attack. Half of this group will receive a new combination of medicine called sacubitril/valsartan. The other half will receive valsartan on its own, which is the usual treatment. The effect of each treatment will be assessed over the course of a year using an MRI scanner to look at the heart muscle, along with blood tests that reveal markers of heart muscle damage. If their results show that sacubitril/valsartan is more effective than valsartan alone, it could pave the way for a larger study to see whether it can reduce the number of people who suffer from heart failure after a heart attack, and improve survival.
Project details
| Grant amount | £306,153 |
|---|---|
| Grant type | Project Grants |
| Application type | Project Grant |
| Start Date | 12 February 2018 |
| Duration | 3 years |
| Reference | PG/17/23/32850 |
| Status | In Progress |
